Semaglutide May Reverse Damage Caused by Osteoarthritis, Study Suggests

Medical researchers report that semaglutide could help undo the disabling tissue damage associated with osteoarthritis, the most prevalent form of arthritis worldwide.

Best known as the active ingredient in Ozempic and Wegovy-widely used for type 2 diabetes management and weight loss-semaglutide appears, in this new work, to safeguard joints in mice via a mechanism that is not simply explained by reduced joint loading from losing weight.

Why semaglutide and osteoarthritis are being studied together

Osteoarthritis is strongly influenced by body weight, but its progression is also driven by wider metabolic and inflammatory factors. Obesity, metabolic conditions such as diabetes, and chronic inflammation can accelerate deterioration across multiple tissues, including bone, cartilage, and the synovium (the lubricating membrane lining the inner surfaces of joints).

Semaglutide-based medicines act by mimicking glucagon-like peptide 1 (GLP-1), a naturally occurring hormone that prompts insulin release to help regulate blood glucose. GLP-1 signalling also supports appetite control by signalling satiety to the brain, which contributes to weight reduction.

It is therefore tempting to assume any osteoarthritis improvement would be purely mechanical-less body mass means less load through the joints. However, symptom relief does not necessarily mean the underlying disease process has been altered. Most existing osteoarthritis treatments are primarily palliative: they can reduce pain and stiffness, yet they do not reliably halt or reverse structural damage.

A weight-loss-independent effect on cartilage in mice

In both mice and humans with obesity and osteoarthritis, semaglutide treatment was associated with less pain and reduced cartilage degeneration. In the mouse work specifically, researchers also observed fewer bone spurs and milder lesions in the joint membranes.

When the team compared cartilage from treated versus untreated mice, they identified altered expression across almost 8,300 proteins, pointing to widespread biological changes within joint tissue.

A key experimental safeguard strengthened the argument that weight loss was not the sole driver. The study included a “pair-feeding” control group given the same food intake as the semaglutide-treated mice. Despite similar changes in body weight, the pair-fed animals did not show the same cartilage protection, implying a weight-loss-independent effect within the joint itself.

The authors write that the findings “highlight the potential off-target effect of semaglutide as an effective drug to treat metabolic osteoarthritis” and also “reveal a weight loss-independent repair mechanism”.

The proposed pathway: GLP-1R-AMPK-PFKFB3 axis

The researchers suggest the most significant pathway influenced by semaglutide is the “GLP-1R-AMPK-PFKFB3 axis”-a linked set of signals that shapes how cells generate and use energy.

By setting off this enzymatic cascade, semaglutide appears to shift the metabolic programme of chondrocytes (the cells responsible for producing and maintaining healthy cartilage), making energy production more efficient and supporting cell survival.

In osteoarthritis-affected mice, the team found chondrocytes derived most of their energy from glycolysis. Because glycolysis does not require oxygen, it can supply energy rapidly under stressful conditions-such as that morning dash to catch the rubbish lorry-but it yields only two net ATP (energy-providing) molecules per glucose molecule.

After semaglutide treatment, however, oxidative phosphorylation (OXPHOS) became the preferred metabolic route in chondrocytes. Unlike glycolysis, OXPHOS uses oxygen and can generate far more ATP-up to 36 molecules per glucose molecule-per unit of glucose.

Randomised human trial: semaglutide added to sodium hyaluronate (HA)

To explore whether the animal findings might translate to people, the researchers ran a randomised human trial involving 20 participants aged 50–75 with both obesity and osteoarthritis. Participants were divided into two groups:

• One group received sodium hyaluronate (HA), a joint-lubricating and particularly effective form of hyaluronic acid
• The other group received HA plus semaglutide

By the end of the 24-week treatment period, the HA+semaglutide group reported lower osteoarthritis pain scores and marked improvements in knee function. MRI assessment also indicated thicker cartilage and signs of recent cartilage growth in inner, weight-bearing joint regions responsible for absorbing impact during everyday movement.

What this could mean for global health

The potential implications are substantial. Osteoarthritis affects roughly 600 million people worldwide and is projected to reach one billion cases by 2050. Rates are also rising among younger, physically active populations, increasing the risk of decades of pain, reduced mobility, and disability.

This work adds to a growing body of evidence that GLP-1 medicines may offer benefits beyond weight loss, and it further focuses attention on developing osteoarthritis therapies that target metabolism inside the joint, rather than only treating symptoms.

Additional considerations for real-world use

If semaglutide’s joint-protective effects are confirmed, practical questions will follow: which patients benefit most (for example, those with obesity-related “metabolic osteoarthritis”), how long treatment would need to continue, and whether it could be paired with non-pharmacological care such as strengthening programmes, activity modification, and weight-management support. Understanding how these approaches complement each other will be essential for meaningful, sustained improvements in pain and function.

Another important issue is monitoring and measurement. Future studies may need to combine symptom scores with imaging (such as MRI) and biochemical markers of cartilage turnover to show clearly whether semaglutide is changing disease trajectory-not merely improving how patients feel.

Caution: early findings and known drawbacks

Expectations should remain measured. Results in mice do not always predict durable outcomes in humans, and semaglutide use carries its own side effects and concerns.

As the researchers conclude, “The protective effects of semaglutide on the human knee joint should be interpreted with caution and require further validation by clinical trials.”

This research was published in Cell Metabolism.